KiraGen Bio

Name

KiraGen Bio

Legal name

KiraGen Bio

Website

https://kiragenbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Cell & Gene Therapy / Oncology Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Multiplex gene editing
• CAR-T cell therapy
• Solid tumor immunotherapy
• AI drug discovery
• Allogeneic cell therapy

Headquarters

HQ city

Allston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing and Partnership Deals: The company partners with biopharma companies, academic teams, and developers to embed multiplex edits that make immune cells resistant to TME-driven suppression. KiraLOGIC edits are modular, programmable, and ready to embed into engineered systems including logic gates and kill switches. Revenue generated through partnership agreements, licensing fees, and co-development collaborations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

KiraGen Bio develops multiplex gene-edited, off-the-shelf (allogeneic) CAR-T cell therapies designed to remain functional in the suppressive tumor microenvironment of solid tumors, beginning with glioblastoma (GBM) as the first clinical target. The company pairs these cell therapy candidates with its KiraLOGIC AI platform, which designs and optimizes combinations of gene edits from real phenotypic data, and its TME-Guards editing methodology that knocks out suppression-sensing receptors.

Product overview

KiraGen Bio is a biotechnology company developing multiplex gene-edited, off-the-shelf CAR-T cell therapies for solid tumors. The company's product portfolio centers on two key offerings: KiraLOGIC, an AI-powered platform that designs and optimizes multiplex gene edit combinations, and TME-Guards, the core editing methodology that knocks out suppression-sensing receptors to make immune cells resistant to tumor microenvironment pressure. The therapies target glioblastoma (GBM) as the first indication and are applicable across solid and blood tumors using alpha-beta T, NK, and gamma-delta T cells. All programs use an allogeneic (donor-derived) chassis optimized for TME resistance.

Differentiator

Problem solved

Functional benefit

Brands

• KiraLOGIC: AI-powered platform that designs multiplex gene edits to keep immune cells functional under tumor microenvironment pressure. It learns from real phenotypes including cytotoxicity, cytokine release, RNA-seq, and persistence in 3D tumor models.

Products and services

• KiraLOGIC Platform AI-powered design platform used to generate, rank, and optimize multiplex gene edit combinations that keep immune cells functional under tumor microenvironment pressure; available to KiraGen Bio and partners for designing TME-resistant cell therapy edits across CAR, TCR, and TIL programs and across αβ T, NK, and γδ T cells.
• Off-the-Shelf Allogeneic CAR-T Cell Therapies Off-the-shelf, donor-derived allogeneic cell therapies that are multiplex gene-edited to resist tumor microenvironment suppression and maintain durable function, developed for biopharma partners and ultimately for solid tumor patients beginning with glioblastoma (GBM) as the lead indication.
• KiraLOGIC Edit Licensing and Partnership Program Partnership and licensing program that supplies KiraGen Bio's modular, programmable multiplex gene edits and KiraLOGIC-designed TME-resistance edits to biopharma companies, academic teams, and cell therapy developers for embedding into existing engineered cell therapy platforms.

Quantifiable outcome

• Solid tumors suppress T cells through multiple overlapping, non-redundant mechanisms - validating need for multiplex rather than single-target approaches

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• LabCentral & C10 Labs AI BioHubflagshipStrategic or Co-development Partner · 12 July 2025KiraGen selected for inaugural cohort of AI BioHub, a bold initiative from LabCentral and C10 Labs in Kendall Square. Backed by $1.9M grant from MassTech, the program provides cutting-edge wet lab + compute infrastructure, curated AI-native biotech community, hands-on support from leaders like Anna Marie Wagner and Shahid Azim, and entrepreneurial programming with investor access. Designed to close the gap between AI promise and experimental reality.
• LabCentralcoreStrategic or Co-development PartnerBoston-based biotech incubator and innovation hub providing startup support and infrastructure for AI-driven biotech companies.
• C10 LabscoreStrategic or Co-development PartnerAI-focused biotech accelerator partner collaborating with LabCentral on the AI BioHub initiative.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Beam Therapeutics: Clinical-stage base editing company founded by KiraGen co-founders' former employer; developing multiplex gene editing approaches including BEAM-201 (CAR-T). Direct competitor in multiplex CAR-T editing with substantially greater capital and clinical-stage assets.
• CRISPR Therapeutics: Commercial-stage gene editing company with approved Casgevy therapy and clinical-stage allogeneic CAR-T programs (CTX112). Larger incumbent with established gene editing platform and cell therapy programs.

Direct peers

• Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapy with clinical-stage assets across multiple hematologic and solid tumor indications. Directly comparable on the allogeneic platform chassis and solid tumor CAR-T focus.
• Caribou Biosciences: Clinical-stage CRISPR gene editing company developing allogeneic CAR-T cell therapies (CB-010, CB-012, CB-011) using multiplex editing approaches. Closest direct competitor on allogeneic + multiplex gene editing combination.
• Fate Therapeutics: Clinical-stage company developing off-the-shelf, iPSC-derived cell therapies including CAR-T and NK cell programs targeting solid and liquid tumors. Comparable on allogeneic platform and multiplex editing for solid tumors.
• Cellectis:

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kiragenbio
• Xx.com/KiraGenBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KiraGen Bio